[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ECSP066694A - TRANSDERMAL ADMINISTRATION HORMONES THAT DO NOT NEED PENETRATION POTENTIATORS - Google Patents

TRANSDERMAL ADMINISTRATION HORMONES THAT DO NOT NEED PENETRATION POTENTIATORS

Info

Publication number
ECSP066694A
ECSP066694A EC2006006694A ECSP066694A ECSP066694A EC SP066694 A ECSP066694 A EC SP066694A EC 2006006694 A EC2006006694 A EC 2006006694A EC SP066694 A ECSP066694 A EC SP066694A EC SP066694 A ECSP066694 A EC SP066694A
Authority
EC
Ecuador
Prior art keywords
hormones
patch
potentiators
transdermal administration
need
Prior art date
Application number
EC2006006694A
Other languages
Spanish (es)
Inventor
Michael Dittgen
Stefan Bracht
Petra Huber
Thomas Langguth
Dirk Schenk
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34702342&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP066694(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of ECSP066694A publication Critical patent/ECSP066694A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7076—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención se refiere a un parche que comprende una capa de droga con un bajo contenido de hormonas, como por ejemplo gestodeno, y opcionalmente un estrógeno (por ejemplo etinilestradiol). Al aplicar el parche a una mujer, se consiguen niveles en plasma de al menos 1,0 ng/ml de gestodeno en condiciones de estado estacionario sin necesidad de incorporar potenciadores de penetración ni mejoradores de permeación en la capa que contiene droga. También son satisfactorios los niveles en plasma de las hormonas que se consiguen durante todo un período de al menos 1 semana, haciendo que el parche se pueda aplicar para utilizarlo en anticoncepción femenina con el concepto de aplicar el parche una vez a la semanaThe present invention relates to a patch comprising a drug layer with a low content of hormones, such as, for example, gestin, and optionally an estrogen (for example ethinyl estradiol). By applying the patch to a woman, plasma levels of at least 1.0 ng / ml of signodene are achieved under steady state conditions without the need to incorporate penetration enhancers or permeation enhancers in the drug-containing layer. Plasma levels of hormones that are achieved over a period of at least 1 week are also satisfactory, making the patch can be applied for use in female contraception with the concept of applying the patch once a week

EC2006006694A 2003-12-12 2006-07-11 TRANSDERMAL ADMINISTRATION HORMONES THAT DO NOT NEED PENETRATION POTENTIATORS ECSP066694A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52871803P 2003-12-12 2003-12-12
EP03078881 2003-12-12

Publications (1)

Publication Number Publication Date
ECSP066694A true ECSP066694A (en) 2006-10-31

Family

ID=34702342

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006694A ECSP066694A (en) 2003-12-12 2006-07-11 TRANSDERMAL ADMINISTRATION HORMONES THAT DO NOT NEED PENETRATION POTENTIATORS

Country Status (15)

Country Link
JP (1) JP4965263B2 (en)
KR (1) KR101168449B1 (en)
CN (1) CN1913878B (en)
AU (1) AU2004298930B2 (en)
BR (1) BRPI0417530B8 (en)
CA (1) CA2549916C (en)
CU (1) CU23868B1 (en)
EA (1) EA011160B1 (en)
EC (1) ECSP066694A (en)
IL (1) IL176112A (en)
MX (1) MXPA06006682A (en)
NO (1) NO341989B1 (en)
NZ (1) NZ548091A (en)
WO (1) WO2005058287A2 (en)
ZA (1) ZA200605713B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2270345T3 (en) 2003-02-21 2007-04-01 Schering Ag STABLE TRANSDERMIC PATCH AGAINST UV RAYS.
US8962013B2 (en) 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
DE102005050729A1 (en) * 2005-10-19 2007-04-26 Schering Ag Method of preventive on-demand hormonal contraception
FR2900048B1 (en) * 2006-04-21 2012-11-16 Oreal COMPOSITIONS COMPRISING A DIPHENYL-METHANE HYDROXYLATED DERIVATIVE
AU2015203180B2 (en) * 2010-09-06 2016-06-30 Bayer Intellectual Property Gmbh Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner)
LT2613772T (en) 2010-09-06 2017-03-27 Bayer Intellectual Property Gmbh Low-dose transdermal patches with high drug release
DE102010040299A1 (en) 2010-09-06 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner)
NZ627242A (en) * 2012-01-27 2016-08-26 Agile Therapeutics Inc Transdermal hormone delivery
JP2018515552A (en) * 2015-05-18 2018-06-14 アジル・セラピューティクス・インコーポレイテッドＡｇｉｌｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Contraceptive composition and methods for improving efficacy and controlling side effects

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0370220B1 (en) * 1988-10-27 1996-01-10 Schering Aktiengesellschaft Gestode composition for transdermal application
US5512292A (en) * 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
AU657502B2 (en) * 1990-10-29 1995-03-16 Alza Corporation Transdermal contraceptive formulations, methods and devices
DE4329242A1 (en) * 1993-08-26 1995-03-02 Schering Ag Agent for transdermal application containing gestodenester
DE4405898A1 (en) * 1994-02-18 1995-08-24 Schering Ag Transdermal therapeutic systems containing sex steroids
EP0787488A4 (en) * 1994-11-18 1998-06-03 Hisamitsu Pharmaceutical Co Percutaneously absorbable patch
PL181582B1 (en) * 1995-06-07 2001-08-31 Ortho Mcneil Pharm Inc Skin sticking plaster and method of administering sole 17-deacetyl norgestimate or together with estrogen
JP4346696B2 (en) * 1996-05-28 2009-10-21 久光製薬株式会社 Transdermal therapeutic device
JP4167750B2 (en) * 1997-04-16 2008-10-22 久光製薬株式会社 Transdermal absorption base and percutaneous absorption preparation containing the base
JP4399044B2 (en) * 1998-10-14 2010-01-13 久光製薬株式会社 Absorption enhancer and transdermal absorption preparation comprising the absorption enhancer
DE19906152B4 (en) * 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Active substance-containing laminates for transdermal systems
KR20010112479A (en) * 1999-07-01 2001-12-20 나까도미 히로다카 Adhesive preparation for percutaneous absorption
DE10053375C1 (en) * 2000-10-27 2002-01-24 Lohmann Therapie Syst Lts Transdermal therapeutic system with light-sensitive agent in polymer matrix and backing, useful for therapy with e.g. nicotine, nifedipine, lacidipine, gestagen, vitamin B 12 or antibiotic, contains colorless ultraviolet absorber
WO2002045701A2 (en) * 2000-12-05 2002-06-13 Noven Pharmaceuticals, Inc. Crystallization inhibition of drugs in transdermal drug delivery systems

Also Published As

Publication number Publication date
CN1913878B (en) 2010-05-26
IL176112A (en) 2011-02-28
JP4965263B2 (en) 2012-07-04
WO2005058287A2 (en) 2005-06-30
NO341989B1 (en) 2018-03-12
AU2004298930A1 (en) 2005-06-30
EA200601089A1 (en) 2006-12-29
BRPI0417530B1 (en) 2018-01-23
KR101168449B1 (en) 2012-07-25
ZA200605713B (en) 2008-01-08
NO20062594L (en) 2006-07-10
MXPA06006682A (en) 2006-08-11
EA011160B1 (en) 2009-02-27
KR20060128910A (en) 2006-12-14
JP2007513938A (en) 2007-05-31
NZ548091A (en) 2009-12-24
BRPI0417530A (en) 2007-03-13
BRPI0417530B8 (en) 2021-05-25
CA2549916C (en) 2013-09-17
CU23868B1 (en) 2013-03-27
CA2549916A1 (en) 2005-06-30
AU2004298930B2 (en) 2009-11-26
WO2005058287A3 (en) 2006-03-02
IL176112A0 (en) 2006-10-05
CN1913878A (en) 2007-02-14
CU20100143A7 (en) 2011-10-31

Similar Documents

Publication Publication Date Title
CR8465A (en) TRANSDERMAL ADMINISTRATION HORMONES THAT DO NOT NEED PENETRATION POTENTIATORS
CU20100143A7 (en) TRANSDERMAL ADMINISTRATION HORMONES THAT DO NOT NEED PENETRATION POTENTIATORS
SE0202857D0 (en) Method and compositions for preventing hormone induced adverse effects
DK0836506T3 (en) Transdermal patch for administration of 17-deacetyl norgestimate alone or in combination with an estrogen
BR0312007A (en) Transcutaneous administration rate control using amorphous pharmaceutical compositions
NO993520L (en) Dosage forms and methods for better erectile dysfunction
AR013520A1 (en) METHOD OF PREPARING A TRANSDERMAL ADMINISTRATION DEVICE, TRANSDERMAL ADMINISTRATION DEVICE AND USE OF A STEROID AS AN ADDITIVE IN A TRANSDERMAL ADMINISTRATION DEVICE
HUP0402213A2 (en) Transdermal therapeutic systems containing steroid hormones and propylene glycol monocaprylate
AR021459A1 (en) PATCH CONTAINING ESTRADIOL FOR THE PERCUTANEOUS APPLICATION OF HORMONES.
PE20040068A1 (en) ETONOGESTREL DECANOATE, UNDECANOATE AND DODECANOATE
ATE382356T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING ESTETROL DERIVATIVES AND USE IN CANCER TREATMENT
UY28668A1 (en) TRANSDERMAL ADMINISTRATION HORMONES THAT DO NOT NEED PENETRATION POTENTIATORS
CU20060121A7 (en) TRANSDERMAL ADMINISTRATION HORMONES THAT DO NOT NEED PENETRATION POTENTIATORS
AR049197A1 (en) HORMONAL CONTRACEPTIVE CONTAINING A COMBINATION OF ETHYLINESTRADIOL AND CLORMADINONE ACETATE
KR960021015A (en) Transdermal Patches
ATE269063T1 (en) FORMULATIONS FOR TRANSDERMAL ADMINISTRATION OF FENOLDOPAM
PL359235A1 (en) Therapeutic agent